Interferon as maintenance therapy in refractory malignant lymphoma.
Patients with refractory malignant lymphoma (RML) have a poor prognosis when treated with conventional chemotherapy, as less than 20% remain alive and free of disease after 5 years. The use of myeloablative chemotherapy followed by BMT has improved the complete remission (CR) rate. Nevertheless, relapse rates remain unchanged, and only a few patients remain alive and free of disease for more than 3 years. For this reason, we began a prospective randomized clinical trial to determine if IFN-alpha2B (5.0 MU three times a week for 1 year) can improve the prognosis in RML. Ninety-six patients with high or high-intermediate clinical risk RML and in CR after intensive chemotherapy were randomly assigned to receive or not to receive IFN as maintenance therapy. A median follow-up of 48.1 months, the time to treatment failure and survival were similar in both groups. Toxicity secondary to IFN administration was mild, and all patients received the planned doses of IFN. We conclude that IFN is not recommended at this dose and schedule as maintenance therapy in patients with RML who achieve CR. Different therapeutic approaches may be developed to improve outcomes for these patients.
Department of Hematology, Oncology Hospital, National Medical Center, México, DF Mexico.
A
A
Avilés
A
A
Talavera
N R
NR
Díaz
N
N
Neri
D000328:Adult; D000368:Aged; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007372:Interferons / Q000627:therapeutic use* / Q000633:toxicity; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome
D007372:Interferons